Estrogen-dependent E2a/Pbxl myeloid cell lines exhibit conditional differentiation that can be arrested by other leukemic oncoproteins

Blood

Volumn 98, Issue 8, 2001, Pages 2308-2318

  Sykes, David B ^a   Kamps, Mark P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CELL SURFACE MARKER; CYTOKINE; ESTROGEN; ESTROGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOX PROTEIN; HYBRID PROTEIN; NUCLEOPORIN 98; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN; PROTEIN ETO; PROTEIN HOXA9; PROTEIN PLZF; RAS PROTEIN; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE MARROW CULTURE; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ESTROGEN ACTIVITY; GENE EXPRESSION; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKEMIA; MONOCYTE; NONHUMAN; PRIORITY JOURNAL;

EID: 0035889142     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.8.2308     Document Type: Article

References (76)

1. Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis. Cell. 1991;64:337-350.
2. Heyworth CM, Dexter TM, Kan O, Whetton AD. The role of hemopoietic growth factors in self-renewal and differentiation of lL-3-dependent multipotential stem cells. Growth Factors. 1990;2:197-211.
3. Valtieri M, Tweardy DJ, Caracciolo D, et al. Cytokine-dependent granulocytic differentiation: regulation of proliferative and differentiative responses in a murine progenitor cell line. J Immunol. 1987; 138:3829-3835.
4. Ichikawa Y. Differentiation of a cell line of myeloid leukemia. J Cell Physiol. 1969;74:223-234.
5. McCormack MP, Gonda TJ. Novel murine myeloid cell lines that exhibit a differentiation switch in response to IL-3 or GM-CSF, or to different constitutively active mutants of the GM-CSF receptor beta subunit [in process citation]. Blood. 2000;95:120-127.
6. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A. 1980;77:2936-2940.
7. Collins SJ. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood. 1987;70:1233-1244.
8. Tsai S, Bartelmez S, Sitnicka E, Collins S. Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development. Genes Dev. 1994;8:2831-2841.
9. Tsai S, Collins SJ. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proc Natl Acad Sci U S A. 1993;90:7153-7157.
10. Lanotte M, Martin-Thouvenin V, Naiman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood. 1991;77:1080-1086.
11. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer. 1976;17:565-577.
12. Mellentin JD, Nourse J, Hunger SP, Smith SD, Cleary ML. Molecular analysis of the t(1;19) breakpoint cluster region in pre-B cell acute lymphoblastic leukemias. Genes Chromosomes Cancer. 1990;2:239-247.
13. Kamps MP, Murre C, Sun XH, Baltimore D. Anew homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell. 1990;60:547-555.
14. Nourse J, Mellentin JD, Galili N, et al. Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell. 1990;60:535-545.
15. Kamps MP, Wright DD. Oncoprotein E2A-Pbxl immortalizes a myeloid progenitor in primary marrow cultures without abrogating its factor-dependence. Oncogene. 1994;9:3159-3166.
16. Picard D. Regulation of protein function through expression of chimaeric proteins. Curr Opin Biotechnol. 1994;5:511-515.
17. Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J. 1989;8:1981-1986.
18. Calvo KR, Knoepfler P, McGrath S, Kamps MP. An inhibitory switch derepressed by pbx, hox, and Meis/Prep1 partners regulates DNA-binding by pbx1 and E2a-pbxl and is dispensable for myeloid immortalization by E2a-pbxl [in process citation]. Oncogene. 1999;18:8033-8043.
19. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138.
20. Herscowitz HB, Reticuloendothelial Society. Manual of Macrophage Methodology: Collection, Characterization, and Function. Immunology Series; 13. New York, NY: Marcel Dekker; 1981.
21. Lu Q, Kamps MP. Heterodimerization of Hox proteins with Pbx1 and oncoprotein E2a-Pbxl generates unique DNA-binding specificities at nucleotides predicted to contact the N-terminal arm of the Hox homeodomain - demonstration of Hoxdependent targeting of E2a-Pbxl in vivo. Oncogene. 1997;14:75-83.
22. Kamps MP, Look AT, Baltimore D. The human t(1;19) translocation in pre-B ALL produces multiple nuclear E2A-Pbxl fusion proteins with differing transforming potentials. Genes Dev. 1991;5:358-368.
23. Khanna-Gupta A, Kolibaba K, Zibello TA, Berliner N. NB4 cells show bilineage potential and an aberrant pattern of neutrophil secondary granule protein gene expression. Blood. 1994;84:294-302.
24. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90:489-519.
25. Yamanaka R, Lekstrom-Himes J, Barlow C, Wynshaw-Boris A, Xanthopoulos KG. CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis [review]. Int J Mol Med. 1998;1:213-221.
26. Zhang DE, Hohaus S, Voso MT, et al. Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promoters. Curr Top Microbiol Immunol. 1996; 211:137-147.
27. Ward AC, Loeb DM, Soede-Bobok AA, Touw IP, Friedman AD. Regulation of granulopoiesis by transcription factors and cytokine signals. Leukemia. 2000;14:973-990.
28. Anderson KL, Smith KA, Conners K, McKercher SR, Maki RA, Torbett BE. Myeloid development is selectively disrupted in PU.1 null mice. Blood. 1998;91:3702-3710.
29. Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem. 1998;273:28545-28548.
30. Gonda TJ, Ramsay RG, Johnson GR. Murine myeloid cell lines derived by in vitro infection with recombinant c-myb retroviruses express myb from rearranged vector proviruses. EMBO J. 1989;8:1767-1775.
31. Lutterbach B, Hiebert SW. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene. 2000;245:223-235.
32. Shen WF, Rozenfeld S, Kwong A, Kom ves LG, Lawrence HJ, Largman C. HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Mol Cell Biol. 1999;19:3051-3061.
33. Magli MC. The role of homeobox genes in hematopoiesis. Biotherapy. 1998;10:279-294.
34. Tong B, Grimes HL, Yang TY, et al. The Gfi-1B proto-oncoprotein represses p21WAF1 and inhibits myeloid cell differentiation. Mol Cell Biol. 1998; 18:2462-2473.
35. Ahn MY, Huang G, Bae SC, Wee HJ, Kim WY, Ito Y. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO. Proc Natl Acad Sci U S A. 1998;95:1812-1817.
36. Dhulipala PD, Lee L, Rao VN, Reddy ES. Fli-1b is generated by usage of differential splicing and alternative promoter. Oncogene. 1998;17:1149-1157.
37. Spyropoulos DD, Pharr PN, Lavenburg KR, et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol. 2000;20:5643-5652.
38. Du Y, Tsai S, Keller JR, Williams SC. Identification of an interleukin-3-regulated aldoketo reductase gene in myeloid cells which may function in autocrine regulation of myelopoiesis. J Biol Chem. 2000;275:6724-6732.
39. Boulukos KE, Pognonec P, Sariban E, Bailly M, Lagrou C, Ghysdael J. Rapid and transient expression of Ets2 in mature macrophages following stimulation with cMGF, LPS, and PKC activators. Genes Dev. 1990;4:401-409.
40. Calvo KR, Sykes DB, Pasillas M, Kamps MP. Hoxa9 immortalizes a granulocyte-macrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced meis expression [in process citation]. Mol Cell Biol. 2000;20:3274-3285.
41. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1 B. Oncogene. 1995;11:2667-2674.
42. Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1 B-dependent transcriptional activation. Mol Cell Biol. 1995;15:1974-1982.
43. Borrow J, Shearman AM, Stanton VP Jr, et al. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9 [see comments]. Nat Genet. 1996;12:159-167.
44. Nakamura T, Largaespada DA, Lee MP, et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet. 1996;12:154-158.
45. Kasper LH, Brindle PK, Schnabel CA, Pritchard CE, Cleary ML, van Deursen JM. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol Cell Biol. 1999; 19:764-776.
46. Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J. 2001;20:350-361.
47. Nakamura T, Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG. Cooperative activation of Hoxa and Pbx1 -related genes in murine myeloid leukaemias [see comments]. Nat Genet. 1996;12:149-153.
48. , Afonja O, Smith JE Jr, Cheng DM, et al. MEIS1 and HOXA7 genes in human acute myeloid leukemia [in process citation]. Leuk Res. 2000;24:849-855.
49. Berliner N, Hsing A, Graubert T, et al. Granulocyte colony-stimulating factor induction of normal human bone marrow progenitors results in neutrophil-specific gene expression. Blood. 1995;85:799-803.
50. Kamps MP, Baltimore D. E2A-Pbxl, the t(1;19) translocation protein of human pre-B-cell acute lymphocytic leukemia, causes acute myeloid leukemia in mice. Mol Cell Biol. 1993;13:351-357.
51. Fu X, Kamps MP. E2a-Pbxl induces aberrant expression of tissue-specific and developmentally regulated genes when expressed in NIH 3T3 fibroblasts. Mol Cell Biol. 1997;17:1503-1512,
52. McWhirter JR, Goulding M, Weiner JA, Chun J, Murre C. A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbxl. Development. 1997;124:3221-3232.
53. de Lau WB, Hurenkamp J, Berendes P, Touw IP, Clevers HC, van Dijk MA. The gene encoding the granulocyte colony-stimulating factor receptor is a target for deregulation in pre-B ALL by the t(1;19)-specific oncoprotein E2A-Pbxl. Oncogene. 1998;17:503-510.
54. Smith KS, Jacobs Y, Chang CP, Cleary ML. Chimeric oncoprotein E2a-Pbxl induces apoptosis of hematopoietic cells by a p53-independent mechanism that is suppressed by Bcl-2. Oncogene. 1997;14:2917-2926.
55. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1 but not Pbx1 b. EMBO J. 1998;17:3714-3725.
56. Perkins A, Kongsuwan K, Visvader J, Adams JM, Cory S. Homeobox gene expression plus autocrine growth factor production elicits myeloid leukemia. Proc Natl Acad Sci U S A. 1990;87:8398-8402.
57. Kohzaki H, Ito K, Huang G, Wee HJ, Murakami Y, Ito Y. Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2. Oncogene. 1999;18:4055-4062.
58. Du C, Redner RL, Cooke MP, Lavau C. Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes [in process citation]. Blood. 1999;94:793-802.
59. Ruthardt M, Testa U, Nervi C, et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Mol Cell Biol. 1997;17:4859-4869.
60. He LZ, Guidez F, Tribioll C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet. 1998;18:126-135.
61. He L, Bhaumik M, Tribioli C, et al. Two critical hits for promyelocytic leukemia. Mol Cell. 2000;6:1131-1141.
62. Culligan DJ, Stevenson D, Chee YL, Grimwade D. Acute promyelocytic leukaemia with t(11;17)(q23;q12-21) and a good initial response to prolonged ATRA and combination chemotherapy. Br J Haematol. 1998;100:328-330.
63. Jansen JH, de Ridder MC, Geertsma WM, et al. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood. 1999;94:39-45.
64. Licht JD, Shaknovich R, English MA, et al. Reduced and altered DNA-binding and transcriptional properties of the PLZF-retiroic acid receptor-alpha chimera generated in t(ll;17)-associated acute promyelocytic leukemia. Oncogene. 1996;12:323-336.
65. Feldman BJ, Reid TR, Cleary ML Pim1 cooperates with E2a-Pbxl to facilitate the progression of thymic lymphomas in transgenic mice. Oncogene. 1997;15:2735-2742.
66. Feldman BJ, Hampton T, Cleary ML. A carboxyterminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PEX1 transgenic mice. Blood. 2000;96:1906-1913.
67. Lanza C, Gaidano G, Cimino G, et al. p53 gene inactivation in acute lymphoblastic leukemia of B cell lineage associates with chromosomal breakpoints at 11q23 and 8q24. Leukemia. 1995;9:955-959.
68. Devaraj PE, Foroni L, Kitra-Roussos V, Secker-Walker LM. Detection of BCR-ABL and E2A-PBX1 fusion genes by RT-PCR in acute lymphoblastic leukaemia with failed or normal cytogenetics. Br J Haematol. 1995;89:349-355.
69. de Groot RP, Coffer PJ, Koenderman L. Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell Signal. 1998;10:619-628.
70. Coffer PJ, Koenderman L, de Groot RP. The role of STATs in myeloid differentiation and leukemia. Oncogene. 2000;19:2511-2522.
71. Enver T, Heyworth CM, Dexter TM. Do stem cells play dice? Blood. 1998;92:348-351; discussion 352.
72. Metcalf D. Lineage commitment and maturation in hematopoietic cells: the case for extrinsic regulation. Blood. 1998;92:345-347; discussion 352.
73. Darley RL, Burnett AK. Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors. Exp Hematol. 1999;27:1599-1608.
74. Katagiri K, Hattori S, Nakamura S, Yamamoto T, Yoshida T, Katagiri T. Activation of Ras and formation of GAP complex during TPA-induced monocytic differentiation of HL-60 cells. Blood. 1994;84:1780-1789.
75. White JR, Gordon-Smith EC, Rutherford TR. Downregulation of Ras gap expression in K562 cells correlates with increased differentiation to macrophages but does not affect cell proliferation or survival. Biochem Biophys Res Commun. 1996;229:504-510.
76. Hogg A, Schirm S, Nakagoshi H, et al. Inactivation of a c-Myb/estrogen receptor fusion protein in transformed primary cells leads to granulocyte/macrophage differentiation and clown regulation of c-kit but not c-myc or cdc2. Oncogene. 1997;15:2885-2898.